TREE NEWS update: Eli Lilly said its drug Foundayo is associated with a reduction in long-term predicted risk of type 2 diabetes and cardiovascular disease. The finding links the treatment to lower modeled risk scores for the two conditions over the long term. No further figures or trial details were disclosed.
Eli Lilly: Foundayo Linked to Lower Long-Term Predicted Risk of Type 2 Diabetes and Cardiovascular Disease
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
16m ago
BoE’s Mann: Risk Management Approach Appropriate Given Inflation Risks
20m ago
China’s National Day Holiday Box Office Tops 200 Million Yuan on Opening Day
26m ago
France’s Budget Watchdog Calls 2027 Growth Forecast Too Optimistic
29m ago
US Trade Rep Greer: Europe Must Act on Overcapacity, Release Diesel Stocks
38m ago
2-Year US Treasury Yield Falls 3bps to 4.86% as Yields Ease
43m ago
Kashkari: Diesel and Truck Driver Supply Top Concern in Minneapolis Fed District